Methadone, a synthetic narcotic analgesic is part of a category called opioids. This opioid has pharmacologic actions qualitatively similar to morphine. Methadone is generally used as a pain reliever and as a part of drug addiction detoxification and maintenance therapy. Pain can be of various types such as due to surgery, strain, and others. A person experiencing severe and chronic pain is given small doses of methadone, which encounters the pain by changing the way the brain and nervous system respond to pain. Opiate dependence is a major public health problem.
Key players are focusing on mergers and acquisitions to strengthen their position in the global methadone hydrochloride market. For instance, in May 2016, Hikma Pharmaceuticals PLC acquired Roxane Laboratories, Inc., a pharmaceutical company. Through this acquisition, the company expanded its product portfolio of opiate agonist by acquiring methadone hydrochloride from Roxane Laboratories, Inc
- This report studies the current scenario as well as the future market potential of methadone hydrochloride across the globe. The market for methadone hydrochloride has been segmented on the basis of formulation, application, route of administration, distribution channel, and region.
- This report provides in-depth analysis of the global methadone hydrochloride market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020-2027)
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, regional outlook, and competitive strategies adopted by the leading players.
- It profiles leading players in the global methadone hydrochloride market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future market expansion and marketing tactics
- Key companies covered as a part of this study are Eli Lilly and Company, Sanofi S.A, Hikma Pharmaceuticals PLC, Mallinckrodt Pharmaceuticals, Siegfried Holding AG, Johnson Matthey, Tianjin Central Pharmaceutical Co., Ltd, Temad Co, Embio LTD, Harman Finochem Ltd, and Rusan Pharma Ltd.
- The global methadone hydrochloride market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
- Stakeholders would greatly benefit in decision-making through various strategy matrices used in analyzing the global methadone hydrochloride market
-
-
- Opiate Withdrawal
- Chronic Pain
- Others
-
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
-
- Eli Lilly and Company
- Sanofi S.A
- Hikma Pharmaceuticals PLC
- Mallinckrodt Pharmaceuticals
- Siegfried Holding AG
- Johnson Matthey
- Tianjin Central Pharmaceutical Co., Ltd
- Temad Co
- Embio LTD
- Harman Finochem Ltd
- Rusan Pharma Ltd
